Table 1 |
||
|
Characteristics1) of the study populations and genotype distribution. |
||
|
ECRHS-Basel N = 418 (%) |
SAPALDIA N = 6003 (%) |
|
|
|
||
|
Female proportion |
211 (50.5) |
3022 (50.3) |
|
Age [years] |
43.4 (± 7.0) |
41.3 (± 11.4) |
|
Age range [years] |
29.3 to 55.1 |
18.2 to 61.8 |
|
Hay fever cases2) |
192 (45.9) |
1105 (18.4) |
|
Asthma cases3) |
78 (18.2) |
369 (6.2) |
|
Eczema cases4) |
200 (47.9) |
2383 (39.7) |
|
Elevated total IgE cases5) |
101 (24.9) |
1168 (21.6) |
|
Allergen sensitization cases6) |
178 (42.6) |
1620 (29.1) |
|
Non-atopic controls7) |
125 (29.9) |
2953 (49.2) |
|
|
||
|
1) Presented in N (%) for categorical and in mean (± SD) for continuous variables. 2) Self-reported hay fever cases answered yes to, Have you ever had a problem with sneezing or a runny nose or a blocked nose when you did not have a cold?', irrespective of self-reported asthma or eczema. 3) Physician-diagnosed asthma cases answered twice yes to 'Have you ever had asthma? Was this confirmed by a doctor?', irrespective of self-reported hay fever or eczema. 4) Self-reported eczema cases answered yes to 'Have you ever had eczema or any other kind of skin allergy?', irrespective of self-reported asthma or hay fever. 5) Elevated total IgE cases had serum total IgE level >100 kU/L, measured by CAP system (Pharmacia) 6) Allergen sensitization cases had at least one allergen specific IgE >0.35 kU/L, measured by CAP system (Pharmacia) for ECRHS-BS and by Phadiatop test (CAP FEIA system, Pharmacia) for SAPALDIA. 7) Non-atopic controls were free of self-reported hay fever, self-reported eczema and physician-diagnosed asthma. |
||
|
Imboden et al. Clinical and Molecular Allergy 2006 4:9 doi:10.1186/1476-7961-4-9 |
||
